Protalix reports Q2 net income of $19.3M on Elfabrio sales and $20M milestone

Protalix BioTherapeutics, Inc.

2023-Q2 EPS reported $0.18 revenue$44,663,000

Revenue from goods $15.1M (+344% YoY) driven by Elfabrio sales to Chiesi after FDA/EMA approvals.
License & R&D revenue $20.0M (+270% YoY) from $20M regulatory milestone payment from Chiesi.
Net income $19.3M ($0.29 basic EPS) vs net loss of $5.3M in Q2 2022; cash $48.2M.
Elfabrio received US FDA (May 10) and EU (May 5) approval for adult Fabry disease; launched in US by Chiesi.
PRX-115 phase I trial for severe gout ongoing; 16 patients dosed to date.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Protalix BioTherapeutics, Inc. reported financial results for three months ended June 30, 2023.

Period: three months ended June 30, 2023
Result: reported results

Exact text from the filing

On August 7, 2023, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023 and provided a business update on recent regulatory, clinical and corporate developments.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Protalix BioTherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-013481

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.